Neomorph Announces Closing of $100 Million Series B Financing

Neomorph 宣布完成 1 亿美元的 B 轮融资

Financing will support the ongoing Phase 1/2 trial of NEO-811 for the treatment of locally advanced or metastatic non-resectable clear cell renal cell carcinoma (ccRCC) and the continued advancement of the company’s broader novel molecular glue degrader pipeline

融资将支持NEO-811用于治疗局部晚期或转移性不可切除的透明细胞肾细胞癌（ccRCC）的正在进行的1/2期试验，并推动公司更广泛的新型分子胶降解剂管线的持续发展。

SAN DIEGO, April 13, 2026-- Neomorph, Inc., a biotechnology company pioneering molecular glue degraders to address previously undruggable proteins, today announced the closing of a $100 million Series B financing. The round was led by Deerfield Management with participation from new investors Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, Binney Street Capital of Dana-Farber Cancer Institute, and others..

圣地亚哥，2026年4月13日——Neomorph公司是一家致力于开发分子胶降解剂以解决以往不可成药蛋白的生物技术公司，今天宣布完成了1亿美元的B轮融资。本轮融资由Deerfield Management领投，新投资者包括Regeneron Ventures、Longwood Fund、Alexandria Venture Investments、丹娜法伯癌症研究所的Binney Street Capital等。

“This financing is a testament to the science, strategy, and team we have built at Neomorph, and it provides us with the capital to execute on our most important near-term priorities,” said Phil Chamberlain, D.Phil., Co-Founder, President, and Chief Executive Officer of Neomorph. “We remain focused on executing the Phase 1/2 trial of NEO-811 to generate clinical data that will inform continued development, while advancing a broader pipeline of novel molecular glue degraders against targets that have historically been considered undruggable.

“这项融资证明了我们在Neomorph建立的科学、战略和团队，并为我们提供了执行近期最重要任务所需的资本，” Neomorph联合创始人、总裁兼首席执行官Phil Chamberlain博士表示。“我们仍将专注于执行NEO-811的1/2期临床试验，以生成有助于指导后续开发的临床数据，同时推进更广泛的新分子胶降解剂管道，针对那些历史上被认为不可成药的靶点。”

We are delighted to welcome new partners and grateful for the continued support of our founding investor, Deerfield. We look forward to working together to deliver innovative medicines for patients with significant unmet need.”.

我们非常高兴欢迎新的合作伙伴，并对我们的创始投资者Deerfield的持续支持表示感谢。我们期待共同努力，为有重大未满足需求的患者提供创新药物。

Proceeds from the financing will primarily support the advancement of the ongoing NEO-811 Phase 1/2 trial, a first-in-human, open-label monotherapy study evaluating the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity in patients with locally advanced or metastatic non-resectable clear cell renal cell carcinoma (ccRCC).

融资所得将主要用于支持正在进行的NEO-811一期/二期试验的进展，这是一项首次在人体中进行的开放标签单药治疗研究，评估局部晚期或转移性不可切除的透明细胞肾细胞癌（ccRCC）患者中的安全性、耐受性、药代动力学和初步抗肿瘤活性。

The capital will also support advancement of Neomorph’s pipeline across multiple therapeutic areas, driven by its proprietary platform to unlock targets that have historically been unreachable with conventional drug discovery..

这笔资金还将支持 Neomorph 在多个治疗领域推进其研发管线，该管线由其专有平台驱动，以解锁传统药物发现方法一直无法触及的靶点。

“We believe that Neomorph has built a differentiated platform with the scientific depth to systematically access a vast new target space, as well as a team with the expertise to translate key findings into compelling drug candidates,” said Cam Wheeler, Ph.D., Partner at Deerfield Management and Chair of Neomorph’s board of directors.

“我们相信，Neomorph 已经建立了一个具有科学深度的差异化平台，能够系统地获取广阔的新靶点空间，同时团队也拥有将关键发现转化为引人注目的候选药物的专业知识，”Deerfield Management 合伙人兼 Neomorph 董事会主席 Cam Wheeler 博士表示。

“Additionally, the confidence of leading global pharmaceutical companies, including Novo Nordisk, Biogen, and AbbVie, who have partnered with Neomorph across cardiometabolic disease, rare disease, neurology, oncology, and immunology, speaks to the versatility of this platform and provides multiple potential paths to validation.

“此外，包括诺和诺德、百健和艾伯维在内的全球领先制药公司与Neomorph在心代谢疾病、罕见病、神经学、肿瘤学和免疫学等领域的合作，也证明了该平台的多功能性，并提供了多种潜在的验证途径。"

We are proud to continue supporting Neomorph as the company advances its molecular glue technology through clinical trials and works to redefine the universe of therapeutic targets available to physicians and patients.”.

我们很自豪能够继续支持 Neomorph，因为该公司将其分子胶技术推进到临床试验阶段，并努力重新定义可供医生和患者使用的治疗靶点范围。

About NEO-811

关于NEO-811

NEO-811 is an investigational molecular glue degrader designed to induce targeted degradation of a protein called ARNT, also known as HIF-1β, and fully block a central signaling pathway implicated in ccRCC. By leveraging a differentiated degradation mechanism, NEO-811 has the potential to address underlying tumor biology that remains inadequately treated with current standards of care.

NEO-811 是一种研究性的分子胶降解剂，旨在诱导靶向降解一种名为 ARNT（也称为 HIF-1β）的蛋白质，并完全阻断与 ccRCC 相关的核心信号通路。通过利用差异化的降解机制，NEO-811 有潜力解决当前标准治疗未能充分应对的肿瘤生物学问题。

NEO-811 is currently being evaluated as a monotherapy in a first-in-human Phase 1/2 clinical trial in patients with locally advanced or metastatic non-resectable ccRCC..

NEO-811目前正在进行一项首次人体I/II期临床试验，作为单药治疗局部晚期或转移性不可切除的ccRCC患者。

About Neomorph

关于新形态

Neomorph is a biotechnology company pioneering the discovery and development of molecular glue degraders to unlock new therapeutic possibilities across serious diseases. By engineering neomorphic protein surfaces, Neomorph enables precisely targeted protein degradation of disease drivers that have historically been considered undruggable.

Neomorph是一家生物技术公司，致力于发现和开发分子胶降解剂，以解锁严重疾病领域的新治疗可能性。通过设计新形态蛋白表面，Neomorph实现了对历来被认为不可成药的致病驱动因子的精准靶向蛋白质降解。

As a leader in molecular glue technology, Neomorph has created the world’s largest proprietary molecular glue target space, spanning multiple novel degrons across an expansive portfolio of E3 ubiquitin ligases. The company was founded in 2020. For more information, visit www.neomorph.com and follow us on LinkedIn..

作为分子胶技术的领导者，Neomorph 创建了全球最大的专有分子胶靶标空间，覆盖了广泛的E3泛素连接酶组合中的多个新型降解决定子。公司成立于2020年。欲了解更多信息，请访问 www.neomorph.com 并在LinkedIn上关注我们。

Contact:

联系人：

Investors

投资者

inquiries@neomorph.com

询问@新形态.com

Media

媒体

Sofia Bermudez

索菲亚·贝穆德斯

LifeSci Communications

生命科学传播

sbermudez@lifescicomms.com

斯伯穆德兹@生命科学通讯.com